ClinicalTrials.gov
public full text
Public Domain
Randomized Phase II Study to Assess PD 0332991 in Breast Cancer
This is a Phase II study trying to identify whether short term treatment with PD0332991 yields anti-proliferative response -defined by a low level of Ki67 expression (IHC) at surgery- or induces senescence as determined by SABG expression (IHC) in tumors from patients with early breast cancer non-candidates for neoadjuvant hormonotherapy or chemotherapy, as compared to no treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer Patients#982460
- PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies#856512
- Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212#827347
- Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)#905070
- Olaparib Maintenance Therapy in Metastatic Breast Cancer#868683
Record · ID 905699
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive